Hepatorenal syndrome - Pathology and therapy;Das hepatorenale syndrom - Pathophysiologie und therapie

Intensivmedizin und Notfallmedizin

Volumn 40, Issue 1, 2003, Pages 13-33

  Wiest, R ^a   Lock, G ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Ascites; Hemodynamics; Liver cirrhosis; Renal function

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; DOPAMINE; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PROSTACYCLIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADRENERGIC SYSTEM; ALGORITHM; ASCITES; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY STRUCTURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MULTICENTER STUDY; PATHOGENESIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PLASMA VOLUME; PORTOSYSTEMIC ANASTOMOSIS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; VASOCONSTRICTION;

EID: 0037294803     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-003-0354-7     Document Type: Review

References (113)

1. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L et al (1993) Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105:229-236
2. Helwig FC, Schutz CB (1932) A liver kidney syndrome. Clinical pathological and experimental studies. Surg Gynecol Obstet 55:570-580
3. Hecker R, Sherlock S (1956) Electrolyte and circulatory changes in terminal liver failure. Lancet 2:1221-1225
4. Henriksen JH, Bendtsen F, Sorensen TI, Stadeager C, Ring-Larsen H (1989) Reduced central blood volume in cirrhosis. Gastroenterology 97:1506-1513
5. Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D (1986) Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 27:1204-1209
6. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8:1151-1157
7. Tage-Jensen U, Henriksen JH, Christensen E, Widding A, Ring-Larsen H, Christensen NJ (1988) Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol 6:350-358
8. Vorobioff J, Bredfeldt JE, Groszmann RJ (1983) Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 244:G52-57
9. Benoit JN, Granger DN (1988) Intestinal microvascular adaptation to chronic portal hypertension in the rat. Gastroenterology 94:471-476
10. Korthuis RJ, Kinden DA, Brimer GE, Slattery KA, Stogsdill P, Granger DN (1988) Intestinal capillary filtration in acute and chronic portal hypertension. Am J Physiol 254(3 Pt 1):G339-G345
11. Vorobioff J, Bredfeldt JE, Groszmann RJ (1984) Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 87:1120-1126
12. Sieber CC, Lopez-Talavera JC, Groszmann RJ (1993) Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 104:1750-1754
13. Lee FY, Albillos A, Colombato LA, Groszmann RJ (1992) The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 16:1043-1048
14. Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire JL et al (1989) Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97:1304-1312
15. Guevara M, Bru C, Gines P, Fernandez-Esparrach G, Sort P, Bataller R et al (1998) Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 28(1):39-44
16. Maroto A, Gines P, Arroyo V, Gines A, Salo J, Claria J et al (1993) Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 17:788-793
17. Maroto A, Gines A, Salo J, Claria J, Gines P, Anibarro L et al (1994) Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: prognostic value of resistive index. Hepatology 20:839-844
18. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M et al (2001) Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 121:389-395
19. Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-Lopez F, Rodes J (1981) Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 11:221-229
20. Claria J, Jimenez W, Arroyo V, La Villa G, Lopez C, Asbert M et al (1991) Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 100:494-501
21. Esler M, Dudley F, Jennings G, Debinski H, Lambert G, Jones P et al (1992) Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis. Ann Intern Med 116:446-455
22. Salo J, Gines A, Anibarro L, Jimenez W, Bataller R, Claria J et al (1995) Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology 22:479-487
23. Gines P, Jimenez W, Arroyo V, Navasa M, Lopez C, Tito L et al (1988) Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 8:636-642
24. Arroyo V, Gines P, Rimola A, Gaya J (1986) Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 81(2B):104-122
25. Lang F, Tschernko E, Schulz EOI, Ritter M, Völkl H (1991) Hepatorenal reflex regulating kidney function. Hepatology 14:590-594
26. Ming Z, Smyth DD, Lautt WW (2001) Intrahepatic adenosine triggers a hepatorenal reflex to regulate renal sodium and water excretion. Auton Neurosci 93(1-2):1-7
27. Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ (1998) The sympathetic nervous system in liver disease. J Hepatol 29:328-341
28. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F et al (1980) Hepatic hemodynamics and the reninangiotensin-aldosterone system in cirrhosis. Gastroenterology 78:92-99
29. Boyer TD, Zia P, Reynolds TB (1979) Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77:215-222
30. Perez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J et al (1984) Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 26:72-80
31. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW (1982) Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 96:413-417
32. Arroyo V, Rodes J, Gutierrez-Lizarraga MA, Revert L (1976) Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 21:249-256
33. Tristani FE, Cohn JN (1967) Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest 46:1894-1906
34. DiBona GF (1984) Renal neural activity in hepatorenal syndrome. Kidney Int 25:841-853
35. Rimola A, Gines P, Arroyo V, Camps J, Perez-Ayuso RM, Quintero E et al (1986) Urinary excretion of 6-ketoprostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome). J Hepatol 3:111-117
36. Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Perez-Ayuso RM et al (1983) Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 13(3):271-278
37. Llach J, Gines P, Arroyo V, Salmeron JM, Gines A, Jimenez W et al (1993) Effect of dipyridamole on kidney function in cirrhosis. Hepatology 17: 59-64
38. Solis-Herruzo JA, Duran A, Favela V, Castellano G, Madrid JL, Munoz-Yague MT et al (1987) Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 5:167-173
39. Lebrec D, Kotelanski B, Cohn JN (1979) Splanchnic hemodynamic factors in cirrhosis with refractory ascites. J Lab Clin Med 93:301-309
40. Fernandez J, Navasa M, Ruiz-Del-Arbol L, Moitinho E, Jimenez W, Bosch J et al (2001) Effects of spontaneous bacterial peritonitis (SBP) on systemic and renal hemodynamics and renal function in cirrhotic patients with ascites. J Hepatol 34:73-74
41. Gonzalez-Garcia M, Monescillo A, Pena E, Uman JM, Garcia-Garzon S, Albillos A et al (2001) Estudio porspectivo clinic-hemodinamico del sindrome hepatorenal en la cirrosis hepatica. Rev Esp Enf Dig 93: (Suppl 1) 11
42. Arroyo V, Guevara M, Gines P (2002) Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 122:1658-1676
43. Ma Z, Lee SS (1996) Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 24:451-459
44. Gines P, Ortega R, Uriz J, Calahorra B, Cardenas A, de las Heras G et al (2001) Effect of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A phase II-study. Hepatology 34:186A
45. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W et al (1998) Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27:35-41
46. Greenway CV, Stark RD (1971) Hepatic vascular bed. Physiol Rev 51:23-65
47. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F et al (1980) Hepatic hemodynamics and the reninangiotensin-aldosterone system in cirrhosis. Gastroenterology 78:92-99
48. Willett IR, Esler M, Jennings G, Dudley FJ (1986) Sympathetic tone modulates portal venous pressure in alcoholic cirrhosis. Lancet 2(8513):939-943
49. Ruiz-Del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J (1997) Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 113:579-586
50. Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A et al (1994) Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 154:201-205
51. Papadakis MA, Arieff AI (1987) Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 82:945-952
52. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G et al (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23:164-176
53. Toledo C, Salmeron JM, Rimola A, Navasa M, Arroyo V, Llach J et al (1993) Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 17:251-257
54. Navasa M, Follo A, Jimenez W, Francitorra A, Planas R, Rimola A et al (1998) Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with development of renal impairment and mortality. Hepatology 27:1227-1232
55. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A et al (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20:1495-1501
56. Arroyo V, Jimenez W (2000) Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 32(Suppl 1):157-170
57. Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME (1969) Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med 280:1367-1371
58. Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH et al (1973) Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N. Engl J Med 289: 1155-1159
59. McCloy RM, Baldus WP, Tauxe WN, Summerskill WH (1967) Plasma volume and renal circulatory function in cirrhosis. Ann Intern Med 66:307-311
60. Gonwa TA, Poplawski S, Paulsen W, Brajtbord D, Goldstein R, Husberg B et al (1989) Pathogenesis and outcome of hepatorenal syndrome in patients undergoing orthotopic liver transplant. Transplantation 47:395-397
61. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB (1991) Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 51:428-430
62. Lerut J, Goffette P, Laterre PF, Donataccio M, Reynaert MS, Otte JB (1995) Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPSS) and liver transplantation. Hepatogastroenterology 42:985-987
63. Seu P, Wilkinson AH, Shaked A, Busuttil RW (1991) The hepatorenal syndrome in liver transplant recipients. Am Surg 57:806-809
64. Moss NG, Powell SL, Falk RJ (1985) Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci USA 82:8222-8226
65. Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, Llach J, Rimola A et al (1993) Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis [see comments]. Hepatology 17:355-360
66. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G (1994) Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 203:72-79
67. Collins IS (1972) Multicentric clinical trial of a vasoconstrictor-ornithine vasopressin (POR-8, Sandoz). N Z Med J 76:77-81
68. Lenz K, Hortnagl H, Druml W, Grimm G, Laggner A, Schneeweisz B et al (1989) Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut 30:90-96
69. Lenz K, Hortnagl H, Druml W, Reither H, Schmid R, Schneeweiss B et al (1991) Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 101:1060-1067
70. Salo J, Gines A, Quer JC, Fernandez-Esparrach G, Guevara M, Gines P et al (1996) Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 25:916-923
71. Gulberg V, Bilzer M, Gerbes AL (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30:870-875
72. Salerno F, Incerti P, Badalamenti S, Lorenzano E, Graziani G, Morganti A et al (1990) Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis. Arch Intern Med 150:65-69
73. Bennett WM, Keeffe E, Melnyk C, Mahler D, Rosch J, Porter GA (1975) Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 135:964-971
74. Hadengue A, Moreau R, Bacq Y, Gaudin C, Braillon A, Lebrec D (1991) Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study. Hepatology 13:111-116
75. Angeli P, Violpin R, Gerunda G, Craighero R, Roner P, Merenda R et al (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29:1690-1697
76. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W et al (1998) Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27:35-41
77. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P et al (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122:923-930
78. Duhamel C, Mauillon J, Berkelmans I, Bourienne A, Tranvouez JL (2000) Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 95:2984-2985
79. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D et al (1998) Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29:565-570
80. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, Di M, V et al (2002) Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14:153-158
81. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-Del-Arbol L et al (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341:403-409
82. Nicholls KM, Shapiro MD, Kluge R, Chung HM, Bichet DG, Schrier RW (1986) Sodium excretion in advanced cirrhosis: effect of expansion of central blood volume and suppression of plasma aldosterone. Hepatology 6:235-238
83. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM et al (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33(1):43-48
84. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J et al (2001) Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 64:15-19
85. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S et al (1998) Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 28:937-943
86. Sieber CC, Groszmann RJ (1992) In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 262:G996-1001
87. Wiest R, Groszmann R (2001) Octreotide potentiates local vasoconstriction in superior mesenteric arteries: mechanism and pharmacodynamics in portal hypertensive and control rats. Gastroenterology eingereicht 120:973-985
88. Albillos A, Colombato LA, Lee FY, Groszmann RJ (1993) Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats. Gastroenterology 104:575-579
89. McCormick PA, Seifalian AM, Stansby G, McGann G, Collins P, Chin J et al (1993) Superior mesenteric artery blood flow in man measured with intra- arterial Doppler catheters: effect of octreotide. J Hepatol 17:20-27
90. Durkin RJ, Winter SM (1995) Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine. Crit Care Med 23:202-204
91. Pehl C, Schepp W (2000) Successful therapy of hepatorenal syndrome with norepinephrine. Z Gastroenterol 38:945-950
92. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Metreau J (2002) Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 36:374-380
93. Guevara M, Gines P (2002) Managment of ascites and hepatorenal syndrome. Prevention and Intervention in Liver Disease - Postgraduate Course - EASL 2002. Madrid, Spain 176-187
94. Ariyan S, Sweeney T, Kerstein MD (1975) The hepatorenal syndrome: recovery after portacaval shunt. Ann Surg 181:847-849
95. Schroeder ET, Numann PJ, Chamberlain BE (1970) Functional renal failure in cirrhosis. Recovery after portacaval shunt. Ann Intern Med 72:923-928
96. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H et al (2000) Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47:288-295
97. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W et al (1998) Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28:416-422
98. Michl P, Gulberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL (2000) Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: Effects in patients with organic or functional renal failure. Scand J Gastroenterol 35:654-658
99. Gerbes AL, Gulberg V, Waggershauser T, Holl J, Reiser M (1998) Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 28:683-688
100. Wong F, Sniderman K, Liu P, Blendis LM (1997) The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 112:899-907
101. Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B et al (1999) Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353(9149):294-295
102. Cade R, Wagemaker H, Vogel S, Mars D, Hood-Lewis D, Privette M et al (1987) Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med 82:427-438
103. Eckardt KU, Frei U (2000) Reversibility of hepatorenal syndrome in an anuric patient with child C cirrhosis requiring haemodialysis for 7 weeks. Nephrol Dial Transplant 15: 1063-1065
104. Perez GO, Golper TA, Epstein M, Oster JR (1996) Dialysis hemofiltration, and other extracorporal techniques in the treatment of renal complications of liver disease. In: Epstein M, editor. The kidney in liver disease. Philadelphia: Hanley and Belfus 517-528
105. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD et al (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6:277-286
106. Kaffy F, Borderie C, Chagneau C, Ripault MP, Larzilliere I, Silvain C et al (1999) Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. J Hepatol 30:174
107. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Metreau J (2001) Noradrenalin for treatment of type 1 hepatorenal syndrome. J Hepatol 34:103A
108. Lake JR, Ring E, LaBerge J, Gordon R, Roberts J, Ascher N (1993) Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. Transplant Proc 25: 1766-1767
109. Spahr L, Fenyves D, N'Guyen VV, Roy L, Legault L, Dufresne MP et al (1995) Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 90:1169-1171
110. Sturgis TM (1995) Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol 20:241-243
111. Alam J, Bass NM, LaBerge J, Ring E, Somberg KA (1995) Treatment of hepatorenal syndrom with the transjugular intrahepatic portosystemic shunt (TIPS). Gastroenterol 108[4]:A1024
112. Brensing KA, Textor J, Strunk H, Klehr HU, Sauerbruch T (1997) Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 349:697-698
113. Ochs A, Rössle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V et al (1995) The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. New Engl J Med 332:1192-1197